Kshipra Empricals Powers Innovation: New API Mfg Unit in Madhya Pradesh

Kshipra Empricals' Life Science Intermediates Project is poised to make a significant impact on the pharmaceutical industry with its focus on producing crucial intermediates and APIs. By setting up a manufacturing unit in Maksi, the project aims to reduce India's dependency on imported LSIs, particularly Pyridine-based compounds, while exploring export opportunities to enhance the country's pharmaceutical exports.

Key features of the project include its capacity to produce LSIs and APIs, with a strong emphasis on sustainability through the establishment of a 1200 square meter green belt. The project's estimated cost of ₹8 Crore is allocated across various components, including land development, plant machinery, and effluent treatment plants, ensuring comprehensive infrastructure.

The project's potential benefits extend beyond import substitution and export potential. By providing cost-effective LSIs to domestic API manufacturers, it could lead to reduced drug prices, benefiting consumers. Additionally, the project is expected to create job opportunities in Maksi and surrounding areas, contributing to local economic development.

News by Rahul Yelligetti